[[Fosmidomycin]]

CATEGORIES: Antibiotics, Oxidoreductase inhibitors, Phosphonic acids

Fosmidomycin is an antibiotic that was originally isolated from culture broths of bacteria of the genus Streptomyces.[tpl]cite journal|last=Iguchi|first=E|coauthors=Okuhara, M, Kohsaka, M, Aoki, H, Imanaka, H|title=Studies on new phosphonic acid antibiotics. II. Taxonomic studies on producing organisms of the phosphonic acid and related compounds.|journal=The Journal of antibiotics|year=1980|volume=33|issue=1|pages=19–23|pmid=7372546|url=http://www.journalarchive.jst.go.jp/japanese/jnlabstract_ja.php?cdjournal=antibiotics1968&cdvol=33&noissue=1&startpage=18[/tpl] It specifically inhibits DXP reductoisomerase, a key enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. It is a structural analogue of 2-C-methyl-D-erythrose 4-phosphate. It inhibits the E. coli enzyme with a KI value of 38 nM (4), MTB at 80 nM, and the Francisella enzyme at 99 nM.Jawaid, S., Seidle, H., Zhou W, Abdirahman, H., Abadeer, M, Hix, JH, van Hoek, ML and RD Couch.  Kinetic Characterization and Phosphoregulation of the Francisella tularensis 1-Deoxy-D-Xylulose 5-Phosphoate Reductoisomerase (MEP Synthase), PLOS One, 4(12): e8288. [tpl]doi|10.1371/journal.pone.0008288[/tpl]

==Use in malaria==

The discovery of the non-mevalonate pathway in malaria parasites has indicated the use of fosmidomycin and other such inhibitors as antimalarial drugs.[tpl]cite journal |last=Jomaa |first=H |authorlink= |coauthors=et al. |year=1999 |title=Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs |journal=Science |volume=285 |issue=5433 |pages=1573–6 |doi=10.1126/science.285.5433.1573 |url= |accessdate= |quote= |pmid=10477522 [/tpl] Indeed, fosmidomycin has been tested in combination treatment with clindamycin for treatment of malaria with favorable results.[tpl]cite journal |last=Borrmann |first=S |authorlink= |coauthors=et al. |year=2004 |title=Fosmidomycin-clindamycin for Plasmodium falciparum infections in African children |journal=J Infect Dis |volume=189 |issue=5 |pages=901–8 |doi=10.1086/381785 |url= |accessdate= |quote= |pmid=14976608 [/tpl][tpl]cite journal |last=Borrmann |first=S |authorlink= |coauthors=et al. |year=2006 |title=Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria |journal=Antimicrob Agents Chemother |volume=50 |issue=8 |pages=2713–8 |doi=10.1128/AAC.00392-06 |url= |accessdate= |quote= |pmid=16870763 |pmc=1538678 [/tpl][tpl]cite journal |last=Ruangweerayut |first=R |authorlink= |coauthors=et al. |year=2008 |title=Assessment of the pharmacokinetics and dynamics of two combination regimens of fosmidomycin-clindamycin in patients with acute uncomplicated falciparum malaria |journal=Malaria J |volume=7 |issue= 1|pages=225 |doi=10.1186/1475-2875-7-225 |url= |accessdate= |quote= |pmid=18973702 |pmc=2600645 [/tpl] It has been shown that an increase in copy number of the target enzyme (DXP reductoisomerase) correlates with in vitro fosmidomycin resistance in the lethal malaria parasite, Plasmodium falciparum.[tpl]cite journal |last=Dharia |first=NV |authorlink= |coauthors=et al. |year=2009 |title=Use of high-density tiling microarrays to globally identify mutations and elucidate mechanisms of drug resistance in Plasmodium falciparum |journal=Genome Biology |volume=10 |issue= 2|pages=R21 |doi=10.1186/gb-2009-10-2-r21 |url= |accessdate= |quote= |pmid=19216790 |pmc=2688282 [/tpl]

==References==


